Tag Archive for: cutaneous t-cell lymphoma

4SC AG: AGM highlights – Positive progress in 2023/2024 leaves company well positioned for resminostat commercialisation

Planegg-Martinsried, Germany, 20 June 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today publishes a summary of key highlights from its Annual General Meeting held earlier today in Martinsried, Germany. Read more…

4SC publishes Q1 2024 report

Planegg-Martinsried, Germany, 18 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today published its Q1 2024 report, presenting all material developments up to 31 March 2024, as well as the Company’s current outlook. The full report is available for […]

4SC AG provides results for financial year 2023 and outlook for 2024

Planegg-Martinsried, Germany, 22 March 2024 – 4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 2023, presenting all material reporting period developments and providing an outlook for 2024. The full report is available at 4SC’s website. Jason Loveridge, Ph.D., CEO of 4SC, commented: “2023 was a real breakout year for […]

4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)

Planegg-Martinsried, Germany, 1 March 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), announced today that it has filed its Marketing Authorisation Application (MAA) for resminostat (Kinselby) with the European Medicines Agency (EMA) and that its MAA has been accepted by […]

4SC AG – Company Update

Planegg-Martinsried, Germany, 20 December 2023 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), announced today that, having incurred a loss amounting to half of its issued share capital, it will convene an Extraordinary General Meeting of shareholders for the 7th February […]